News

Abstract submission deadline: Tuesday, 26 July 2022 Trial in Progress (“TiP”) abstracts Exactis-01: Clinical Utility of Returning Liquid Biopsy NGS Results in NSCL Cancer Patients – A Canadian Trial through the Exactis Network (NCT04564079) Karen Gambaro 1 , Maud Marques 1 , Andrea Hébert-Losier 1 , Suzan McNamara 1 ,...
Plenary themes under which authors will submit their abstracts: • Registries, research and health policy PERSONALIZE MY TREATMENT (PMT): A CANADIAN CANCER PATIENT REGISTRY. Maud Marques 1 , Karen Gambaro 1 , Vincent Normandeau-Babin 1 , David Bouffard 1 , Ethan Hoang 1 , Suzan McNamara 1 , the Exactis...
We are pleased to announce that Dr. Kostas Trakas has been appointed CEO of Exactis Innovation, effective February 1, 2022.
We are pleased to have been chosen among the 39 best clinical trial companies in Canada according to the site: https://beststartup.ca/ Here is a summary of the article: This article showcases our top picks for the best Canada based Clinical Trials companies. These startups and companies are taking a variety...
Since their initial description in 19481, small DNA fragments travelling in the non-cellular component of internal bodily fluids and excretions have revolutionized numerous fields in public health and preventive medicine2,3,4,5,6. Although its origins have been a topic of controversy, cell-free DNA (cfDNA) is generally thought to arise from cellular breakdown...
Exactis Innovation is a pan-Canadian research network that accelerates biomarker-led clinical and translational research in areas of high-unmet medical need. Precision Medicine in Cancer Care The past decade has seen the emergence of precision medicine, a complicated method of cancer treatment in which different molecular variants found in tumours guide...
Study of lasofoxifene versus fulvestrant in patients with metastatic breast cancer will include seven precision-medicine Exactis Network study locations COLUMBUS, Ohio (September 29, 2020) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female oncology products in the precision medicine metastatic breast cancer arena, today...
Exactis is pleased to be working with Dr. Jonathan Spicer on a phase I interventional pilot open-label trial, using rhDNase1 as a treatment for COVID-19 positive patients. The objectives are to assess the safety and feasibility of inhaled rhDNase1 in severely ill COVID-19 patients requiring admission, to evaluate the impact...
The Exactis-01 trial, a PMT sub-study “Multi-centre Observational Study to Evaluate the Clinical Utility of Returning Genomic Aberration Results Using the Oncomine Precision Assay (OPA) in Advanced or Metastatic NSCLC within the Exactis Network” will be open at several PMT sites and Princess Margaret Hospital, the PI of the study...
The Exactis-03 trial “A  Phase I/II Basket Trial of the Combination of PARP inhibitor and Navitoclax in  Women with High Grade Serous Epithelial Ovarian Cancer and Triple Negative Breast Cancer” led by Dr. Helen MacKay from Sunnybrook Hospital, will be opened across PMT Network sites and Princess Margaret Hospital. Phase I will define the dose and schedule of navitoclax...
1 2 3